We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
Read MoreHide Full Article
Key Takeaways
IBRX shares rose 7% after reporting Q1 2026 revenues of ~$44.2M, up 168% year over year.
ImmunityBio growth is driven by rising Anktiva adoption, with unit sales also expected to jump 168%.
IBRX is advancing Anktiva studies and label expansions, targeting broader bladder and multiple cancer uses.
ImmunityBio’s (IBRX - Free Report) shares rose 7%, following the release of better-than-expected preliminary product revenues for first-quarter 2026.
IBRX’s top line primarily comprises product sales from Anktiva, an IL-15 receptor agonist, which is the company's lead product and commercial growth driver. The drug is approved in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
Anktiva has now secured approvals across five regulatory jurisdictions, covering around 34 countries.
Year to date, shares of IBRX have rallied 277.7% compared with the industry’s 2.1% growth.
Image Source: Zacks Investment Research
Q1 2026 Preliminary Results
ImmunityBio expects net product revenues to be approximately $44.2 million in the first quarter of 2026, suggesting 168% year-over-year growth and a 15% sequential increase, driven by steady post-launch adoption. The preliminary figure beat the Zacks Consensus Estimate of total revenues of $41 million. IBRX’s total revenues comprise product revenues and a small amount of other revenues. Anktiva unit sales volume is expected to increase 168% year over year for the first quarter of 2026.
The company ended the quarter with a solid liquidity position of approximately $380.9 million in cash, cash equivalents, and marketable securities, up from $242.8 million in the fourth quarter of 2025.
IBRX Advances the Development of Anktiva
ImmunityBio is pursuing additional label expansion opportunities for Anktiva. It recently resubmitted a supplemental regulatory filing with the FDA seeking label expansion for the combination of Anktiva and BCG in BCG-unresponsive NMIBC with papillary disease.
Within bladder cancer, IBRX is advancing a randomized study evaluating Anktiva plus BCG in BCG-naïve NMIBC patients — a significantly larger population than the currently approved setting. The company is targeting a potential regulatory filing later this year, with additional studies exploring the therapy across other disease settings that could further expand its addressable market.
Beyond bladder cancer, ImmunityBio is exploring Anktiva, in combination with standard-of-care therapies and CAR-NK approaches, across several difficult-to-treat cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma, colorectal cancer and hepatocellular carcinoma. In January, the therapy received its first regulatory approval in the NSCLC indication in Saudi Arabia. The company intends to hold discussions with the FDA later this year, seeking label expansion for the drug in a similar indication.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 9.68% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 9.95% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.14 to $8.99. Year to date, shares of ANIP have declined 1.52%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
Key Takeaways
ImmunityBio’s (IBRX - Free Report) shares rose 7%, following the release of better-than-expected preliminary product revenues for first-quarter 2026.
IBRX’s top line primarily comprises product sales from Anktiva, an IL-15 receptor agonist, which is the company's lead product and commercial growth driver. The drug is approved in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
Anktiva has now secured approvals across five regulatory jurisdictions, covering around 34 countries.
Year to date, shares of IBRX have rallied 277.7% compared with the industry’s 2.1% growth.
Image Source: Zacks Investment Research
Q1 2026 Preliminary Results
ImmunityBio expects net product revenues to be approximately $44.2 million in the first quarter of 2026, suggesting 168% year-over-year growth and a 15% sequential increase, driven by steady post-launch adoption. The preliminary figure beat the Zacks Consensus Estimate of total revenues of $41 million. IBRX’s total revenues comprise product revenues and a small amount of other revenues. Anktiva unit sales volume is expected to increase 168% year over year for the first quarter of 2026.
The company ended the quarter with a solid liquidity position of approximately $380.9 million in cash, cash equivalents, and marketable securities, up from $242.8 million in the fourth quarter of 2025.
IBRX Advances the Development of Anktiva
ImmunityBio is pursuing additional label expansion opportunities for Anktiva. It recently resubmitted a supplemental regulatory filing with the FDA seeking label expansion for the combination of Anktiva and BCG in BCG-unresponsive NMIBC with papillary disease.
Within bladder cancer, IBRX is advancing a randomized study evaluating Anktiva plus BCG in BCG-naïve NMIBC patients — a significantly larger population than the currently approved setting. The company is targeting a potential regulatory filing later this year, with additional studies exploring the therapy across other disease settings that could further expand its addressable market.
Beyond bladder cancer, ImmunityBio is exploring Anktiva, in combination with standard-of-care therapies and CAR-NK approaches, across several difficult-to-treat cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma, colorectal cancer and hepatocellular carcinoma. In January, the therapy received its first regulatory approval in the NSCLC indication in Saudi Arabia. The company intends to hold discussions with the FDA later this year, seeking label expansion for the drug in a similar indication.
ImmunityBio’s Zacks Rank & Stocks to Consider
IBRX currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals (ANIP - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 9.68% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 9.95% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.14 to $8.99. Year to date, shares of ANIP have declined 1.52%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.